Lexaria Bioscience Corp. (LEXX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, LEXX carries an RQD Score of 34 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 7 of 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns or free cash flow to shareholders. The whale 13F flow pillar scores 5 of 20 and the insider conviction pillar scores 5 of 20, both pointing to weak institutional and insider support in the rating model. The macro regime fit pillar scores 6 of 20 with a beta of 1.0. The forensic balance sheet pillar scores 11 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 4 of 9, and a Debt/Equity of 0.5. For a prospective investor evaluating the stock today, the rating's implication is that upside drivers would need to come from catalysts rather than from current earnings or cash generation, and that valuation rests on an unproven operating base with negative margins. The rating model's verdict is a caution signal, not a personalized recommendation.

Per the SEC financials, revenue rose from $0.2M in FY 2023 to $0.7M in FY 2025, while operating losses widened to $-11.9M in FY 2025. Per the market data, net margin is -60% and ROIC is -35%, confirming the company is not yet profitable. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4 of 9, with a Debt/Equity of 0.5. Cash of $4.3M is reported for FY 2025 against an FCF outflow of $-10.5M in the same year.

Per the recent news feed, the most recent item is a Stock Titan report of an SEC filing dated Oct 14, 2026, flagged YELLOW under MARKET WIRE. A Yahoo! Finance Canada seasonal returns chart and a GuruFocus intellectual property item are also flagged YELLOW. A Benzinga item lists LEXX among health care stocks moving in after-market trading, flagged YELLOW. A Stock Titan report on an oral tablet formula tested against Wegovy is flagged GREEN under CATALYST, the only catalyst-category item. An Investing.com Nigeria report states the company received four patents for drug delivery technology, flagged YELLOW. Risk watch items include the widening operating loss and the negative FCF documented in the SEC financials. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What are the specific revenue sources behind the $0.7M FY 2025 revenue, and how much is recurring versus one-time?
• What is the reported EPS, debt balance, and cash position for FY 2024 and FY 2023, which the source data marks as N/A or not reported?
• What is the company's cash runway given the $-10.5M FY 2025 FCF outflow against $4.3M of cash?
• What are the status and commercial timing of the drug delivery patents and the oral tablet formula referenced in the news feed?
• What trailing and forward earnings or EV/EBITDA metrics apply, given that the P/E, EV/EBITDA, and EPS fields are unavailable?